Novavax Sees Unusually Large Options Volume (NASDAQ:NVAX)

Share on StockTwits

Novavax, Inc. (NASDAQ:NVAX) was the target of unusually large options trading on Monday. Stock investors purchased 1,217 put options on the company. This represents an increase of approximately 1,366% compared to the typical volume of 83 put options.

Shares of NVAX opened at $5.22 on Tuesday. Novavax has a one year low of $3.54 and a one year high of $51.60. The stock has a 50-day moving average price of $4.34 and a 200 day moving average price of $5.21. The company has a market capitalization of $128.90 million, a P/E ratio of -0.52 and a beta of 1.96.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.24. The business had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $4.40 million. During the same quarter in the prior year, the firm earned ($2.40) earnings per share. Sell-side analysts anticipate that Novavax will post -5.7 earnings per share for the current year.

Several brokerages recently commented on NVAX. Citigroup dropped their target price on Novavax from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, September 24th. Zacks Investment Research downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. B. Riley started coverage on shares of Novavax in a research report on Wednesday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. Cantor Fitzgerald reiterated a “neutral” rating on shares of Novavax in a research note on Thursday, October 17th. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $27.50 target price on shares of Novavax in a research report on Friday, November 8th. Three analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.85.

In other news, SVP John A. Herrmann III sold 3,643 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $7.07, for a total value of $25,756.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO John Trizzino sold 5,578 shares of the company’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $5.72, for a total value of $31,906.16. Following the completion of the sale, the chief financial officer now directly owns 4,800 shares of the company’s stock, valued at approximately $27,456. The disclosure for this sale can be found here. Insiders have sold a total of 22,770 shares of company stock valued at $132,123 in the last quarter. Company insiders own 3.30% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Novavax by 473.7% during the third quarter. Tower Research Capital LLC TRC now owns 7,166 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 5,917 shares during the last quarter. Rhumbline Advisers increased its holdings in Novavax by 10.3% in the third quarter. Rhumbline Advisers now owns 33,428 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 3,118 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Novavax during the second quarter valued at approximately $197,000. A.R.T. Advisors LLC acquired a new stake in Novavax during the second quarter valued at approximately $435,000. Finally, Creative Planning lifted its holdings in Novavax by 16.5% during the 3rd quarter. Creative Planning now owns 92,344 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 13,101 shares during the last quarter. 26.74% of the stock is owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Featured Article: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.